RxDoctor Payments Data

Rajiv Patel, DO

Cardiovascular Disease · Hackensack, NJNPI 1134311756

Payments from drug & device makers

$32,945in general payments, 2019–2025

Across 362 payments — averaging $91.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$24K
  • Abbott$4K
  • Abiomed$1K
  • Novartis$525
  • AstraZeneca$512
  • Amgen$470
  • plus $3K from 25 others

What the payments were for

  • Speaking & faculty fees$12,00036%
  • Travel & lodging$6,01818%
  • Food & beverage$14,92645%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,945 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$676,598
Medicare patients
1,416
Services billed
7,332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$155,535
XareltoRivaroxaban66$84,385
EntrestoSacubitril/Valsartan29$33,255
JardianceEmpagliflozin20$26,015
EdarbiAzilsartan Medoxomil57$24,243
MultaqDronedarone Hcl20$22,352
Repatha SureclickEvolocumab22$21,009
FarxigaDapagliflozin Propanediol22$18,308
VerquvoVericiguat13$18,228
Praluent PenAlirocumab14$6,834
Benicar HctOlmesartan/Hydrochlorothiazide13$5,186
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide89$4,221
Metoprolol Succinate201$4,027
Ranolazine ErRanolazine36$3,984
Atorvastatin Calcium169$2,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$300$155,535113 claims
Johnson & JohnsonXarelto$263$84,38566 claims
NovartisEntresto$525$33,25529 claims
Boehringer IngelheimJardiance$302$26,01520 claims
Arbor Pharmaceuticals, Inc.Edarbi$110$24,24357 claims
Sanofi-aventis U.S. LLCMultaq$44$22,35220 claims
AstraZenecaFarxiga$512$18,30822 claims
MerckVerquvo$166$18,22813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →